Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Nivolumab in Metastatic Renal Cell Carcinoma: NCT06863311 Clinical Landscape Report 2026
15 October 2026
NCT06863311 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Axitinib in Advanced Renal Cell Carcinoma: NCT06860386 Clinical Landscape Report 2026
15 October 2026
NCT06860386 clinical landscape for Advanced Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Diffuse Large B-Cell Lymphoma: NCT06863402 Clinical Landscape Report 2026
15 October 2026
NCT06863402 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Obinutuzumab in Diffuse Large B-Cell Lymphoma: NCT06867536 Clinical Landscape Report 2026
15 October 2026
NCT06867536 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LCAR-AIO(Legend Biotech) in Autoimmune Diseases: NCT06866080 Clinical Landscape Report 2026
15 October 2026
NCT06866080 clinical landscape for Autoimmune Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Metastatic Renal Cell Carcinoma: NCT06866262 Clinical Landscape Report 2026
15 October 2026
NCT06866262 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
PF-08046032 in Peripheral T-Cell Lymphoma: NCT06870487 Clinical Landscape Report 2026
15 October 2026
NCT06870487 clinical landscape for Peripheral T-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nivolumab in Mediastinal large B-cell lymphoma: NCT06871007 Clinical Landscape Report 2026
15 October 2026
NCT06871007 clinical landscape for Mediastinal large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Octreotide pamoate in Recurrent Cervical Cancer: NCT06865677 Clinical Landscape Report 2026
15 October 2026
NCT06865677 clinical landscape for Recurrent Cervical Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CGC-738 in Locally Advanced Clear Cell Renal Cell Carcinoma: NCT06870279 Clinical Landscape Report 2026
15 October 2026
NCT06870279 clinical landscape for Locally Advanced Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
FGFR4-CAR T cells(NCI) in Rhabdomyosarcoma: NCT06865664 Clinical Landscape Report 2026
15 October 2026
NCT06865664 clinical landscape for Rhabdomyosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Indocyanine Green in Ovarian Cancer: NCT06871787 Clinical Landscape Report 2026
15 October 2026
NCT06871787 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.